Physician profile
Bharat Gupta
NPI 1114980075
$3,890.33
in general payments reported to CMS, 2019-2025
24 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $128 · 2021: $351 · 2022: $1,257 · 2023: $376 · 2024: $527 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473 · Education: $43.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.85 |
| Education | $43.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $719.92 | 2019-2024 | Tezspire, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $400.42 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $366.00 | 2020-2023 | Acthar, Terlivaz |
| Glaxosmithkline, LLC. | $331.52 | 2019-2025 | Nucala |
| Amgen INC. | $307.57 | 2019-2024 | Otezla, Krystexxa |
| Akebia Therapeutics INC | $232.78 | 2024-2025 | Vafseo |
| Janssen Pharmaceuticals, INC | $230.59 | 2019-2022 | |
| Horizon Therapeutics Plc | $221.08 | 2021-2023 | Krystexxa |
| Galderma Laboratories, L.P. | $125.00 | 2025 | Nemluvio |
| Novo Nordisk INC | $124.99 | 2022 | |
| Pfizer INC. | $124.99 | 2019 | |
| Vifor Pharma, INC. | $120.55 | 2019-2024 | Veltassa |
| Abbott Laboratories | $110.93 | 2019 | |
| Calliditas Therapeutics US INC. | $93.75 | 2025 | Tarpeyo |
| Mylan Specialty L.P. | $91.59 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $69.99 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $48.81 | 2022 | |
| Vantive US Healthcare LLC | $40.50 | 2025 | Renal - Pd |
| Ani Pharmaceuticals, INC. | $25.33 | 2022 | |
| Ardelyx, INC. | $25.00 | 2024 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $24.46 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.40 | 2023 | |
| Leadiant Biosciences, INC. | $18.00 | 2022 | |
| Mallinckrodt Enterprises LLC | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bharat Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.